Artiva Biotherapeutics, Inc. 4

Director Laura Stoppel received an option award for 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share.

On September 8, 2026, director Laura Stoppel was granted a stock option to purchase 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share as a director stock option award. The option vests in full on the earlier of September 8, 2027, or the date of Artiva’s 2027 annual stockholder meeting, and will expire on September 7, 2036 if not exercised. Following this grant, Stoppel beneficially owns 13,750 shares (underlying the option) in a direct capacity, reflecting a routine equity-based compensation award rather than an open-market purchase or sale.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-385419

Alert Tier

5